title: The fetal origins of the metabolic syndrome: can we intervene?
abstract: Epidemiological studies have suggested that metabolic programming begins during fetal life and adverse events in utero are a critical factor in the etiology of chronic diseases and overall health. While the underlying molecular mechanisms linking impaired fetal development to these adult diseases are being elucidated, little is known about how we can intervene early in life to diminish the incidence and severity of these long-term diseases. This paper highlights the latest clinical and pharmaceutical studies addressing how dietary intervention in fetal and neonatal life may be able to prevent aspects of the metabolic syndrome associated with IUGR pregnancies.
authors.affiliation: Departments of Physiology and Pharmacology, and the Department of Obstetrics & Gynecology, The University of Western Ontario, London, ON, Canada N6A 5C1; The Children's Health Research Institute, The Lawson Health Research Institute, London, ON, Canada N6A 4V2.
authors.forename: Noelle
authors.initials: N
authors.lastname: Ma
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Hardy
mesh_terms: D000975:Antioxidants / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000627:therapeutic use; D004035:Diet Therapy; D019587:Dietary Supplements; D000077270:Exenatide; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D005260:Female; D005317:Fetal Growth Retardation / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D005492:Folic Acid / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008550:Melatonin / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D018977:Micronutrients / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D039401:Prenatal Nutritional Physiological Phenomena; D000077185:Resveratrol; D013267:Stilbenes / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use
chemical_list: D000975:Antioxidants; D015525:Fatty Acids, Omega-3; D007004:Hypoglycemic Agents; D018977:Micronutrients; D010455:Peptides; D013267:Stilbenes; D014688:Venoms; D005492:Folic Acid; D000077270:Exenatide; D008550:Melatonin; D001205:Ascorbic Acid; D000077185:Resveratrol